【摘要】 目的:观察门冬胰岛素和生物合成人胰岛素对妊娠期糖尿病(GDM)患者血糖的控制情况以及其对并发症发生率的影响。方法:选取2010年1月~2013年1月在该院住院和门诊治疗的100例未能通过饮食控制、运动和糖尿病教育合理控制血糖的GDM患者为研究对象,随机分为观察组和对照组两组,每组50例,分别给予门冬胰岛素(诺和锐)和生物合成人胰岛素(诺和灵R)进行治疗。结果:观察组血糖在空腹血糖、餐后2 h血糖、夜间血糖及三餐前血糖四个水平上达标的平均天数明显少于对照组,差异有统计学意义(P<0.05);在妊娠期观察组发生并发症的人数少于对照组,差异有统计学意义(P<0.05)。结论:门冬胰岛素的治疗效果在控制血糖和并发症的发生率方面均优于生物合成人胰岛素。更多还原

【Abstract】 Objective: To observe the effects of insulin aspart and biosynthetic human insulin on blood glucose control and incidence rate of complications among patients with gestational diabetes mellitus( GDM). Methods: One hundred GDM patients failing in blood glucose control by diet control,exercise and health education treated in outpatient department and inpatient department of the hospital from January 2010 to January 2013 were selected as study objects,and then they were randomly divided into observation group and control group,50 patients in each group,the patients in the two groups were treated with insulin aspart( NovoRapid) and biosynthetic human insulin( Novolin R) respectively. Results: The mean numbers of days reaching the standards of fasting glucose,postprandial two-hour blood glucose,blood glucose at night and blood glucose before three meals in observation group were statistically significantly less than those in control group( P < 0. 05); the number of patients with complications during pregnancy in observation group was statistically significantly less than that in control group( P < 0. 05). Conclusion: The therapeutic effect of insulin aspart in controlling blood glucose and incidence rate of complications is better than that of biosynthetic human insulin for GDM patients.更多还原